Melpaque HP Cream
Generic Name: hydroquinone
Dosage Form: cream
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
4% CREAM Rx
(HYDROQUINONE 4% USP
SKIN BLEACHING MOISTURIZING
TOPICAL CREAM WITH SUNBLOCK)
FOR EXTERNAL USE ONLY: NOT
FOR OPHTHALMIC, NASAL OR
Melpaque HP Cream Description
Each gram of MELPAQUE® HP 4% CREAM contains ACTIVE: 40mg of Hydroquinone USP in a tinted sunblocking cream base of INACTIVES: Edetate Disodium, Glyceryl Monostearate SE, Iron Oxides, Methyl Paraben, Mineral Oil, Polyoxyl (40) Stearate, Polyoxyethylene (25) Propylene Glycol Stearate, Potassium Sorbate, Propyl Paraben, Propylene Glycol, Purified Water, Sodium Metabisulfite, Squalene, Stearic Acid and Talc.
Hydroquinone is 1, 4-Benzenediol, with a chemical formula of C6H6O2 and a molecular weight of 110.11.
The structural formula is:
Melpaque HP Cream - Clinical Pharmacology
Topical application of hydroquinone produces a reversible depigmentation of the skin by the inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine (DOPA) [Denton, C., et al., 1952 (1)] and suppression of other melanocyte metabolic processes [Jimbow, K., et al., 1974 (2)]. Exposure to sunlight or ultraviolet light will cause repigmentation of the bleached areas [Parrish, J.A. et al., 1978 (3)].
Indications and Usage for Melpaque HP Cream
MELPAQUE® HP 4% CREAM is indicated for the gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines and other undesired areas of melanin hyperpigmentation.
MELPAQUE® HP 4% CREAM is contraindicated in persons who have shown hypersensitivity to hydroquinone or any of the other ingredients. The safety of topical treatment of hydroquinone during pregnancy or in children (12 years and under) has not been established. (See PRECAUTIONS).
1. Hydroquinone is a skin bleaching agent which may produce undesired effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this medication.
2. To evaluate possible susceptibility to irritation or sensitivity, each patient should begin by applying the medication to a small portion of unbroken skin at or near the pigmented area over a period of several days. Minor redness is not necessarily a contraindication, but treatment should be discontinued if itching, excessive inflammation or vesicle formation occurs. Close patient supervision is recommended. Use of MELPAQUE® HP 4% CREAM in paranasal and infraorbital areas increases the chance of irritations (See ADVERSE REACTIONS). If no improvement is seen after two months of treatment, use of this product should be discontinued.
3. Sunscreen use is an essential aspect of hydroquinone therapy since even minimal sunlight exposure stimulates melanocyte activity. The sunblocks in MELPAQUE® HP 4% CREAM provide the necessary sun protection during skin bleaching activity. During the depigmentation maintenance treatment subsequent to the intensive depigmentation therapy, sun exposure of the bleached skin should be avoided to prevent repigmentation.
4. Contains Sodium Metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
5. Keep this and all other medications out of reach of children. In case of accidental ingestion, call a physician or a poison control center immediately.
6. Avoid contact with eyes. In case of accidental contact, patient should rinse eyes thoroughly with water and contact physician. A bitter taste and antiseptic effect may occur if applied to the lips.
Pregnancy Category C
Animal reproduction studies have not been conducted with hydroquinone. It is also not known whether hydroquinone can cause fetal harm when administered on a pregnant woman or can affect reproductive capacity. It is also not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used in pregnant women only when clearly indicated.
It is not known whether topical administration of hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.
Safety and effectiveness in children below the age of 12 years has not been established.
No systemic adverse reactions have been reported. Occasional hypersensitivity (localized contact dermatitis) may occur in which case the medication should be discontinued and the physician notified immediately.
There have been no systemic reactions reported from the use of topical hydroquinone treatment. However, treatment should be limited to relatively small areas of the body at one time since some patients may experience a transient skin reddening and a mild burning sensation which does not preclude treatment.
Melpaque HP Cream Dosage and Administration
MELPAQUE® HP 4% CREAM should be applied to affected areas twice daily, in the morning and before bedtime, or as directed by a physician. Unnecessary solar exposure should be avoided. There is no recommended dosage for children under 12 years of age except under the advice and supervision of a physician. Keep container tightly closed. NOTE: Slight darkening of MELPAQUE® HP 4% CREAM is normal and does not affect potency of the product.
How is Melpaque HP Cream Supplied
MELPAQUE® HP 4% CREAM (Hydroquinone, USP 4%) is supplied as follows:
|1 oz tube (28.35 grams)||58980-473-10|
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F); however, such exposure should be minimized. [See USP Controlled Room Temperature]. Protect from freezing. If freezing occurs, warm to room temperature.
Keep out of the reach of children.
STRATUS PHARMACEUTICALS INC
12379 SW 130TH STREET
MIAMI, FLORIDA 33186
Sonar Products, Inc.
Carlstadt, NJ 07072
Copyright ©1993, Stratus Pharmaceuticals, Inc.
All rights reserved.
1. Denton, C., Lerner, A., and Fitzpatrick, T., "Inhibition of Melanin Formation by Chemical Agents", J. Invest. Derm., 18:119-135, 1952.
2. Jimbow, K., Obata, M., Pathak, M., and Fitzpatrick, T., "Mechanisms of Depigmentation by Hydroquinone" J. Invest. Derm., 62:436-449, 1974.
3. Parrish, J, Anderson, R., Urbach, F., and Pitts, D., " Biological Effects of Ultraviolet Radiation with Emphasis on Human Responses to Longwave Ultraviolet", Plenum Press, New York, 1978 (page 151).
Rev. JG-MPCI 2014-311
PRINCIPAL DISPLAY PANEL - 28.35 g Tube Box
Net WT. 1 oz (28.35g)
MELPAQUE® HP 4% CREAM
(HYDROQUINONE USP, 4%)
SKIN BLEACHING CREAM WITH SUNBLOCKS
Distributed by Stratus Pharmaceuticals Inc, 12379 SW 130th Street, Miami, Florida 33186
|Labeler - Stratus Pharmaceuticals (789001641)|
|Sonar Products, Inc.||104283945||MANUFACTURE(58980-473)|
More about Melpaque HP (hydroquinone topical)
- Side Effects
- During Pregnancy
- Dosage Information
- Support Group
- Pricing & Coupons
- En Español
- 1 Review – Add your own review/rating